Alpha interferon and ribavirin are required in combination to achieve a sustained virological response in the treatment of hepatitis C virus (HCV) infection. Alpha interferon has direct antiviral activity and also enhances HCV-specific T-cell responses. Ribavirin has little direct activity against HCV but reduces hepatic inflammation. It is therefore likely that these drugs in combination have hitherto unidentified immunological effects. In the present study we investigated the effects of alpha interferon and ribavirin on dendritic cell (DC) maturation and cytokine production induced by double-stranded RNA in vitro. Alpha interferon alone enhanced the expression of HLA class I, HLA class II, and CD86 on immature DCs but did not stimulate full DC maturation, which requires the expression of CD83. Alpha interferon enhanced the production of interleukin 12 p70 [IL-12(p70)] and tumor necrosis factor alpha (TNF-␣) but had no effect on IL-10 production. In contrast, ribavirin at physiological doses had no effect on DC maturation but markedly suppressed the production of TNF-␣, IL-10, and IL-12(p70). The suppression of cytokines by ribavirin cannot be explained by the induction of DC apoptosis or cell death. Quantitative PCR confirmed that cytokine suppression occurs at the level of mRNA. The suppression of IL-12(p70) and TNF-␣ in maturing DCs may explain the reduction in hepatic inflammation observed during ribavirin monotherapy. Combination alpha interferon-ribavirin therapy may alter the cytokine profile of maturing DCs overall by suppressing IL-10 production but maintaining IL-12(p70) and TNF-␣ production, a pattern that would favor viral elimination through downstream effects on T cells.Hepatitis C virus (HCV) infection is a global public health problem and a significant cause of patient morbidity and mortality (14). Alpha interferon (IFN-␣) in combination with ribavirin (1--D-ribofuranosyl-1H-1,2,4-triazole-3 carboxamide) is now the mainstay of treatment of HCV infection and leads to sustained viral eradication in 46 to 76% of infected patients, depending on the HCV genotype (13). The mechanisms of action of these drugs are poorly understood. IFN-␣ monotherapy leads to sustained viral eradication in only 8% of infected patients (28), while ribavirin monotherapy has a minimal effect on the viral load but significantly reduces hepatic inflammation (11,15,29). Clearly, then, these drugs have effects, hitherto unidentified, which in combination promote HCV control.During persistent HCV infection, HCV-specific T-cell responses are weak and very difficult to detect ex vivo (19). However, these responses are enhanced during combination therapy (6), and the HCV-specific lymphoproliferative capacity has been associated with a sustained virological response to therapy (9). Furthermore, the enhanced virological response rates seen with pegylated IFN-␣ for the treatment of HCV have been attributed to sustained HCV-specific CD4ϩ -T-cell responses (16). These studies clearly support the hypothesis that long-term viral control...